PMID- 17612902
OWN - NLM
STAT- MEDLINE
DCOM- 20071023
LR  - 20131121
IS  - 0891-6934 (Print)
IS  - 0891-6934 (Linking)
VI  - 40
IP  - 5
DP  - 2007 Jul
TI  - Lack of effect of methimazole on dendritic cell (DC) function and DC-induced 
      Graves' hyperthyroidism in mice.
PG  - 397-402
AB  - In addition to the biochemical inhibition of thyroid hormone synthesis, 
      antithyroid drugs including methimazole (MMI) may have immunosuppressive effect 
      through inhibition of major histocompatibility complex (MHC) class I and II 
      expressions on non-professional (thyrocytes) and professional (macrophages and B 
      cells) antigen presenting cells (APCs). Dendritic cells (DCs) are another 
      professional APCs and very likely play the most important role in the primary 
      immune response. Therefore, we focused in this study on evaluating the effect of 
      MMI on DC function in mice. Bone marrow cells cultured with granulocyte 
      macrophage colony stimulating factor and interleukin (IL)-4 expressed high levels 
      of CD11c and moderate levels of MHC class II, both of which are widely used 
      markers for DCs. In vitro incubation of this DC-containing cell population with 
      10(- 6)-10(- 4) M MMI for 2 days did not change basal- and maturation signal 
      (adenoviral infection and lipopolysaccharide)-induced levels of the cell surface 
      marker expressions such as MHC class I and II, CD86, CD40 and DEC205, and of 
      proinflammatory cytokine IL-6 release. Further we found that treatment of the 
      DC-containing cell population with MMI did not influence the incidence of Graves' 
      hyperthyroidism and anti-thyrotropin receptor (TSHR) antibody titers in a mouse 
      Graves' model we have recently established with DCs infected with adenovirus 
      expressing the TSHR A subunit. Although we cannot completely exclude 
      immunosuppressive effect of MMI on other immune cells, our data indicate that DCs 
      do not appear to be the primary target for the immunosuppressive effect of MMI.
FAU - Mizutori, Yumiko
AU  - Mizutori Y
AD  - Department of Medical Gene Technology, Graduate School of Biomedical Sciences, 
      Atomic Bomb Disease Institute, Nagasaki University, Sakamoto, Nagasaki, Japan. 
      nagayama@nagasaki-u.ac.jp
FAU - Saitoh, Ohki
AU  - Saitoh O
FAU - Eguchi, Katsumi
AU  - Eguchi K
FAU - Nagayama, Yuji
AU  - Nagayama Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Autoimmunity
JT  - Autoimmunity
JID - 8900070
RN  - 0 (Cytokines)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 554Z48XN5E (Methimazole)
SB  - IM
MH  - Animals
MH  - Antigen-Presenting Cells/drug effects/immunology/metabolism
MH  - Cells, Cultured
MH  - Cytokines/immunology/metabolism
MH  - Dendritic Cells/drug effects/*immunology/metabolism
MH  - Female
MH  - Graves Disease/drug therapy/*immunology
MH  - Histocompatibility Antigens/immunology/metabolism
MH  - Immunosuppressive Agents/pharmacology
MH  - Methimazole/*pharmacology/therapeutic use
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Thyroid Gland
MH  - Transfection
EDAT- 2007/07/07 09:00
MHDA- 2007/10/24 09:00
CRDT- 2007/07/07 09:00
PHST- 2007/07/07 09:00 [pubmed]
PHST- 2007/10/24 09:00 [medline]
PHST- 2007/07/07 09:00 [entrez]
AID - 779824813 [pii]
AID - 10.1080/08916930701463485 [doi]
PST - ppublish
SO  - Autoimmunity. 2007 Jul;40(5):397-402. doi: 10.1080/08916930701463485.